COVID-19 Seroprevalence Study in French Guiana
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 3,541
- 试验地点
- 5
- 主要终点
- Measure of the COVID-19 immunity of the population
研究概览
简要总结
Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.
详细描述
Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.
This study is a interventional study that present minimal risks and constraints.
The results of the study will allow estimation of COVID-19 virus infection, severity and attack rates, as well as inform public health responses and policy decisions in the French Guiana territory.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Person going to a prevention and care center or medical biology analysis laboratory as part of the care, regardless age, regardless of an acute or previous infection with COVID-19;
- •State of health compatible with a blood sample as defined in the protocol
排除标准
- •Inability to consent
- •Person under guardianship or curatorship
- •Known pathology or a health problem contraindicated with the collect of blood sample.
结局指标
主要结局
Measure of the COVID-19 immunity of the population
时间窗: 1 year
The COVID-19 immunity of the population will be assessed by evaluating the anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies
次要结局
- Evaluation of the level of asymptomatic and pauci-symptomatic infections(1 year)